How-To Lower Your Heart Disease Risk: A Science-based Action Plan for Cholesterol

Reviewed for scientific and medical accuracy by Jordan Feigenbaum, MD, MS

Cholesterol is often treated like a villain, but you may be surprised to learn that it is actually essential for life. It is involved in things like the structure of our cells, brain and nerve function, and hormone production. It is important enough that every cell in our body can make all the cholesterol it needs to function, without needing high amounts to be delivered from the blood.

So, why are we often warned about it?

The short answer is that the difference between “essential” and “dangerous” often comes down to two things: where it is located, and time.

While it is essential when produced inside our cells for their vital functions, when cholesterol levels stay high in your blood over decades, these particles have more opportunity to slip into artery walls and silently build up plaque, known as atherosclerosis. 

Heart disease and stroke risk isn’t just about how high your numbers are today, but how long they’ve been elevated throughout your whole life. This is also not just a disease of the elderly; cardiovascular disease develops in 1/2 of men before age 65 (and ¼ before 55), and 1/3 of women before age 65 — and for those having their first event like a heart attack, a large fraction are fatal.

This long-term, complex relationship is why cholesterol is so confusing. People can have moderate levels and still suffer a heart attack, while others with high levels never do. This happens because other factors—like smoking, high blood pressure, diabetes, and inflammation—also play a role. However, even in the absence of all those other risks, managing your blood cholesterol levels remains a powerful strategy to protect your heart.

This document will focus on an action plan for blood cholesterol levels. 

Key Takeaways – Cumulative Exposure Matters: Cardiovascular risk is determined by “the lower, the longer, the better.” Your lifetime exposure to ApoB-containing particles is more predictive than a single snapshot in time. – ApoB is the Gold Standard: While LDL-C is the standard measure, ApoB (particle count) is a superior predictor of risk, especially for those with metabolic syndrome or type 2 diabetes. – The Power of Combination: Modern management favors early combination therapy (e.g., low-dose statin + ezetimibe) to achieve aggressive targets rapidly with fewer side effects than high-dose monotherapy. – Lifestyle is the Foundation: A high-fiber diet (30g+ daily) and an improved P:S ratio (replacing saturated fats with unsaturated) are the most potent non-drug tools for lowering LDL and ApoB.

Step 1: How to Test Blood Cholesterol Levels

The first step involves establishing baseline blood cholesterol levels. While many other tests (for example, relating to inflammation or metabolic function) can add information about your cardiovascular health, here we’ll focus on the Standard Lipid Panel, Apolipoprotein B (ApoB), and Lipoprotein(a) [Lp(a)].

For a more detailed dive into blood cholesterol, see our Comprehensive Barbell Medicine Guide to Cholesterol and Barbell Medicine Podcast Episode #165: The Science of Cholesterol.

The Standard Lipid Panel

The Standard Lipid Panel is the foundation. This measures the cholesterol and fats being carried around in your blood by particles called lipoproteins. While testing has historically been done while fasting (on an empty stomach), a non-fasting sample is sufficient in most situations. Fasting provides the most accurate reading of triglyceride levels, but the remaining measures are less affected.

Here is a breakdown of the four numbers on your standard panel:

Total Cholesterol (TC)

The total amount of all cholesterol carried by all lipoproteins in your blood. It gives a “big picture” number but is less useful than the individual components below.

High-Density Lipoprotein-Cholesterol (HDL-C)

Often called the “good” cholesterol, although this is technically misleading, because all cholesterol is the same; what is different is the particle carrying it. In this case, having higher levels of cholesterol on “high-density” lipoprotein particles is associated with better heart health, but treatments targeted at specifically raising this number do not protect you from heart disease. It’s best understood as a marker of good health, not a primary target for treatment. Extremely high levels (above approximately 97 mg/dL in men and 135 mg/dL in women) are paradoxically associated with increased risk. We also see very low levels in patients with diabetes, liver disease, and among those who use anabolic steroids, all of which increase risk.

Triglycerides (TG)

Triglycerides are a form of fat carried on lipoproteins and used by your body for energy. The direct role of triglycerides in heart disease is complex; blood triglycerides can be high while fasting or might increase and remain high long after eating. These elevations are common when people have obesity, diabetes, are physically inactive, and/or are consuming diets characterized by: low fiber, high saturated fat, high refined carbohydrates & sugar, and/or use alcohol. Extremely high levels (greater than 500 mg/dL) require aggressive treatment to prevent a serious condition called pancreatitis.

Low-Density Lipoprotein-Cholesterol (LDL-C)

The LDL particle is the main cholesterol carrier that causes problems. It tends to linger in the bloodstream for long periods of time, giving it the opportunity to enter the walls of your blood vessels, triggering inflammation and plaque buildup. All LDL particles—regardless of minor size differences—are small enough to cause problems. Lowering LDL-C is the primary goal of nearly all effective treatment strategies, mostly by speeding up how quickly it is cleared from the blood.

Apolipoprotein B (ApoB)

While the standard panel measures the amount of cholesterol inside the lipoproteins (the mass of the cargo), Apolipoprotein B (ApoB) measures the total number of lipoprotein particles that contribute to plaque. Since it’s the particle that enters the artery wall, not just the cholesterol mass it carries, ApoB is a more accurate and superior measure of heart disease risk than LDL-C. In many cases, these values match fairly well, although a significant number of people—especially those with diabetes—have results that don’t match up between their LDL-C and ApoB levels. In these cases, the ApoB levels are more reliable and predictive of risk.

While clinical trials show that lowering ApoB reduces risk, Mendelian Randomization studies provide the most compelling evidence for causality. These studies look at people with genetic variations that naturally result in lower ApoB levels from birth. These individuals have a much lower risk of heart disease compared to those who only lower their levels later in life. This confirms that ApoB-containing particles are not just markers of disease, but the actual cause—and that the benefit of low levels is cumulative over a lifetime.

ApoB is a simple and inexpensive blood test, though some doctors may still be unfamiliar with it. In general, maintaining an ApoB level below 90 mg/dL is desirable for most people. However, the highest risk comes from the total lifetime exposure: “the lower, the longer, the better.” 

For those seeking to reduce their lifetime risk as much as possible, for those at very high risk, or for those who have already had a heart attack, lowering ApoB as much as possible is the ideal strategy to minimize future risk.

Lipoprotein(a) 

Lipoprotein(a), or Lp(a), is a unique lipoprotein, similar to LDL, whose blood levels are mostly determined by your genetics. High levels increase the risk of conditions like aortic valve stenosis (a narrowing of the heart valve), as well as heart attacks and strokes. Because your level doesn’t change much throughout life, it’s valuable to measure Lp(a) at least once in your life to estimate your baseline risk.

As of 2025, specific treatments to directly lower Lp(a) are in advanced clinical trials. Until studies show their effectiveness, if you have high Lp(a), the key is to manage your other heart disease risk factors (like LDL-C, blood pressure, smoking, and metabolic health) as aggressively as possible, by treating yourself as a “high risk” patient. This should be done in consultation with a physician. For more information on this topic, check out our dedicated article, Guide to Lipoprotein(a) and Risk Management and accompanying podcast.

As mentioned above, there are many other tests that can be useful for overall cardiovascular risk assessment, however this document is focused on cholesterol and lipid assessment.

Action: Review your most recent blood work. If your doctor only ordered a standard lipid panel, consider asking for an Apolipoprotein B (ApoB) test at your next visit. It is often less than $30 and provides the most accurate assessment of your atherogenic particle count. Want to take these testing requirements to your next doctor’s appointment? Download our printable Cholesterol Action Plan PDF here.

Step 2: Interpretation and Risk Assessment

To translate these individual numbers into a clear plan, we need to identify all the potentially harmful cholesterol particles. We then combine these results with your personal health profile to accurately assess your long-term and short-term cardiovascular risk.

Non-HDL-Cholesterol

When experts talk about a person’s risk, they often use a calculated number called Non-HDL Cholesterol (Non-HDL-C). This number provides a simple estimate of all the cholesterol carried by harmful particles. It’s easy to calculate using your standard panel results: you simply subtract your HDL-C from your Total Cholesterol (TC):

TC – HDL-C = Non-HDL-C

Non-HDL-C estimates all the cholesterol being carried by particles that can potentially cause plaque buildup, including LDL, Lp(a), and Remnant Cholesterol (which we’ll discuss next). Because it captures more of the risk, it’s generally a better predictor of heart disease than LDL-C alone from a standard panel. However, remember that ApoB (the particle count) is still the single best measure when available.

Example Calculation:

• Total cholesterol: 200 mg/dL
• HDL-C: 50 mg/dL
• Non-HDL-C: 200 – 50 = 150 mg/dL

For generally healthy people, a reasonable goal is a Non-HDL-C level less than 100-130 mg/dL, though the risk continues to fall as levels get lower. For those at especially high risk (like those with existing heart disease), the goal is simply to get this level as low as possible to minimize future risk.

Remnant Cholesterol: A Hidden Risk

Remnant Cholesterol is carried on particles that are left over (like VLDL) after your body has used the triglycerides inside them for energy. Remnant cholesterol is more than just an “extra” risk factor; elevated remnants are a hallmark of metabolic syndrome and insulin resistance. When your body struggles to manage blood sugar and insulin, it often results in an overproduction of VLDL particles and a slower clearance of their remnants. This connects your lipid profile directly to your broader metabolic health. If your remnants are high, it is a strong signal to evaluate other markers like waist circumference, blood pressure, and fasting glucose.

These particles can carry up to 40 times more cholesterol than a standard LDL particle. As a result, high levels of remnant cholesterol are an even stronger risk factor for heart disease than LDL-C, and they are also often less responsive to standard cholesterol-lowering drugs.

While remnant cholesterol isn’t directly measured on a standard panel, a high level of Triglycerides (TG) – especially above 150 mg/dL – is often the first sign that remnant cholesterol is also high. You can estimate it using this calculation:

TC – HDL-C – LDL-C = Remnant Cholesterol

The risk is a spectrum: remnant levels below 20 mg/dL are optimal, while levels above 30 mg/dL are very high.

10-Year vs. Lifetime Risk

In practice, your blood cholesterol levels are combined with other variables (age, sex, blood pressure, smoking status, and other factors) to estimate your future risk of a heart event. Current risk estimators can be found here.

A Note on Familial Hypercholesterolemia (FH): If your LDL-C is persistently over 190 mg/dL (or ApoB >130 mg/dL) despite a high-fiber, low-saturated fat diet, you may have a genetic condition called Familial Hypercholesterolemia. In these cases, your body is genetically programmed to have fewer LDL receptors or overproduce particles. For individuals with FH, the risk is “baked in” from birth, making early and aggressive medication therapy essential rather than optional.

10-Year Risk Score: 

This is the most common calculator used for adults aged 40-79 years. It estimates the short-term likelihood of a heart attack or stroke. The major drawback is that it often underestimates the risk for younger people. A 45-year-old with moderately high cholesterol might get a low 10-year score (e.g., 2%) but still face a very high lifetime risk if their risk factors go unmanaged.

30-Year/Lifetime Risk: 

A lifetime risk estimate is a more useful tool for younger adults 20-59, because it highlights the cumulative impact of high cholesterol and other risk factors over decades, providing a more accurate picture of their long-term health trajectory.

Additional Heart Disease Risk Beyond Blood Cholesterol

An apparently low 10-year score should not be the only guide. If you have specific, strong factors that elevate your intrinsic risk (e.g., a family history of early heart disease or high Lp(a)), aggressive intervention may be necessary regardless of the calculated percentage. These other factors include:

• Family history of premature heart disease (before age 55 in men, or 65 in women).
• Established chronic kidney disease or diabetes mellitus.
• Persistently elevated LDL-C above 160 mg/dL, triglycerides over 175 mg/dL, or ApoB over 130 mg/dL.
• Elevated Lipoprotein(a) levels above 50 mg/dL (or 125 nmol/L)
• High-sensitivity C-reactive protein (hs-CRP) above 2.0 mg/L.
• Chronic inflammatory disorders (like rheumatoid arthritis, HIV, lupus, and others).
• Premature menopause before age 40
• Pregnancy complications including pre-eclampsia, gestational diabetes or hypertension
• Individuals of South Asian ancestry
• Known disease based on Coronary Artery Calcium or Ankle-Brachial Index testing

Summary of Treatment Targets

Measurement	Low/Average-Risk	High/Very-High Risk
LDL-C	< 100 mg/dL	< 55 mg/dL or as low as possible
Non-HDL-C	< 130 mg/dL	< 70 mg/dL or as low as possible
ApoB	< 80 mg/dL	< 50 mg/dL or as low as possible
Triglycerides	< 100 mg/dL	< 100 mg/dL
Lipoprotein(a)	0-30 mg/dL = low risk	> 50 mg/dL = high risk

For more information regarding cholesterol levels, treatment targets, and controversy, check out our dedicated article, Cholesterol Myths and Misconceptions and podcast, “Can cholesterol be too low?”.

NOTE: You can also use the automated Lipid Scorecard and Hidden Risk Calculator included in our free Cholesterol Action Plan. It is designed to help you organize these numbers and prepare for your next doctor’s visit.

Coronary Artery Calcium (CAC) Scoring

The Coronary Artery Calcium (CAC) score is a low-radiation CT scan that measures the amount of calcified (hard) plaque that has already built up in the walls of your coronary arteries.

A key point is that the CAC score only detects hard, calcified plaque. This hard plaque is a relatively “stabilized” form of plaque that develops late in the process of atherosclerosis.

What the CAC score does not detect is soft, non-Calcified plaque. This soft plaque is considered less stable and is more prone to rupturing and causing a heart attack. Detecting soft plaque requires a more involved test, such as a CT Coronary Angiography (CCTA). Unlike a standard CAC scan, CCTA uses intravenous contrast to visualize the “soft” non-calcified plaque and the degree of narrowing (stenosis) in the arteries. For high-risk individuals or those with complex clinical pictures, CCTA can provide a deeper look at the current state of the disease.

Aside from the low-dose radiation exposure and cost, there are a few drawbacks to consider:

• A score of zero (CAC=0) suggests a lower short-term risk over the next 5-10 years, but it’s not a 100% guarantee. This is especially true for younger patients.

The utility of a CAC score depends heavily on your age and health status:

• Younger Adults with a CAC score that is GREATER than 0 → highly informative, and indicative of a higher-risk situation. Plaque is present and intervention is warranted. A score of 0 is less informative, since young plaque often hasn’t had time to fully calcify anyway. In this group, blood cholesterol (ApoB, Lp(a)) remains key for long-term risk assessment.
• Older Adults with a CAC score that IS 0 → highly informative, and indicative of a lower-risk situation, The patient has lived long enough to develop calcification, so a zero score is a strong indicator of lower risk over the next decade. If an older patient has already had a heart attack, stroke, or known bypass surgery/stent, the CAC score is irrelevant, as high-risk atherosclerosis has already been established.
• For patients who are debating or reluctant about treatment, the non-invasive Coronary Artery Calcium (CAC) Score can be a useful test to guide subsequent decision making, including timing and aggressiveness of therapy.

Action: If you have your standard panel results but not an ApoB test, calculating your Non-HDL Cholesterol is a good proxy. You can do so by using the following formula:Total Cholesterol – HDL = Non-HDL-CA standard goal is for this number to be below 100 mg/dL. For individuals who have other risk factors or who are looking to “optimize” for longevity, below 70mg/dL would be the target.

Step 3: Diet Plan to Lower Blood Cholesterol (LDL and ApoB)

Diet is the most powerful non-drug method you have for improving your lipid profile. The strategy is built on two principles: replacement (swapping less-healthy foods for healthier foods) and prioritization (emphasizing whole, high-fiber foods).

Eat A Health-Promoting Dietary Pattern

An effective dietary strategy starts with basic general health steps:

• Maintain a Healthy Weight: Achieving and maintaining a healthy level of body weight and body fat. This can be done through diet alone, or with the use of anti-obesity medications and/or surgery. Carrying excess body fat can limit the effectiveness of other cholesterol-lowering treatments.
• Prioritize Whole Foods: Build your plate around nutrient-dense options like vegetables, fruits, legumes, nuts, seeds, and whole grains.
• Limit Processed Foods: Minimize added sugars, liquid calories, and heavily refined or ultra-processed foods, which are low in nutrients and often high in saturated fat and refined carbohydrates.

Dietary Fat Quality: The P:S Ratio

The type of fat you eat has a profound impact on your cholesterol levels. This is largely because fat quality controls how quickly cholesterol is cleared from your blood, and to a lesser extent by how quickly LDL particles are produced in the liver.

• Saturated Fat: Saturated fats (found in foods like butter, lard, coconut oil, and fatty red meat) raise your blood cholesterol by slowing its clearance from the bloodstream.
• Polyunsaturated Fat: Polyunsaturated or monounsaturated fats (from foods like olive oil, avocado, fish, nuts, and seeds) prompt the liver to clear cholesterol faster, lowering circulating levels.
• The P:S Ratio: the ratio of Polyunsaturated-to-Saturated (P:S) fat is a simple way to summarize your diet’s fat quality. A higher P:S ratio lowers heart disease risk. Replacing saturated fats with unsaturated fats is the most potent dietary move you can make for lowering LDL-C.

For more information specifically relating to red meat intake, check out our extensive article on the topic, The Science of Red Meat Intake. 

Dietary Fiber

Eating high-fiber foods is a potent way to lower blood cholesterol levels and heart disease risk.

• The Goal: We recommend consuming at least 30 grams per day of fiber from food. There are benefits to consuming more, so feel free to increase your intake beyond this target if able.
• How it Works: Fiber, especially soluble fiber, works by binding to bile (which is made from cholesterol), and carrying it out of the body instead of allowing it to be re-absorbed in the intestines. Your liver then pulls cholesterol out of the blood in order to make new bile, lowering your circulating levels by speeding up clearance.
• Best Sources: Berries, lentils, beans, edamame, chickpeas, oats, barley, and vegetables. Supplements including psyllium husk, ground flaxseed, and chia seeds can also help meet targets.

Dietary Cholesterol

While dietary cholesterol is often not the first target for intervention, it does have an impact, and remains relevant for two main reasons:

1. Genetic Sensitivity: Some individuals (often called “hyper-responders”) are genetically more sensitive, causing their blood levels to rise significantly with increased dietary cholesterol. The use of statin drugs also increases gut absorption of cholesterol (discussed further below).
2. Synergy with Saturated Fat: Many foods that are high in cholesterol (like fatty cuts of red meat) are also high in the saturated fats you should be replacing anyway, due to the impact of the P:S ratio described above.

In short, focusing on improving your P:S ratio and increasing fiber intake provides the biggest benefit. If further lowering is needed after those steps are taken, limiting foods high in dietary cholesterol may be the next intervention.

To summarize, examples of specific, food-based strategies to improve your blood cholesterol level are listed in Table 1:

Table 1: 

Intervention Category	Actionable Food Swaps & Changes	Rationale/Benefit
Increase Soluble Fiber	Increase consumption of various berries, lentils, beans, edamame, chickpeas, oats, and barley. Consider supplementing with psyllium.	Soluble fiber binds to cholesterol in the digestive system, promoting its excretion and lowering LDL cholesterol.
Replace Saturated Fats	1. Swap butter and coconut oil for olive oil in cooking and dressings.	Olive oil contains monounsaturated fats, which are heart-healthy replacements for saturated fats.
	2. Replace fatty red meat with fish (salmon, tuna, sardines), lean poultry, or legumes (beans, lentils, edamame).	Leaner proteins and fish (rich in omega-3s) help reduce saturated fat intake.
Integrate Healthy Fats	Incorporate walnuts, almonds, flaxseed, or chia seeds.	These provide healthy unsaturated fats and additional fiber.
Choose Plant-Based Proteins	Replace fatty meat servings with tofu, tempeh, or edamame.	Plant-based proteins are naturally low in saturated fat and may further reduce LDL levels.
Other Lifestyle Changes	Substitute unfiltered coffee (like French press or espresso) with coffee prepared through a paper filter.	Reduces the consumption of diterpenes (cafestol and kahweol), which are compounds known to raise LDL cholesterol.
	Reduce alcohol intake, especially for those with high triglycerides.	Excessive alcohol consumption can significantly raise triglyceride levels.

Action:  The P:S Swap: Look at your kitchen staples. Replace one source of saturated fat (butter, coconut oil, or lard) with a high-quality monounsaturated or polyunsaturated source (extra virgin olive oil, avocado oil, or walnut oil).  Replacing saturated fats with unsaturated alternatives improves your P:S ratio, directly lowering LDL-C and ApoB levels.

Step 4: Exercise for Lowering Blood Cholesterol

While exercise is best known for improving metabolic function, helping with weight management, and reducing inflammation, it’s also a powerful tool for optimizing your blood cholesterol. Specifically, aerobic exercise improves the quality and function of your HDL particles, boosts their anti-inflammatory properties, and increases the rate at which LDL and triglycerides are cleared from your blood.

As a result, we recommend exceeding the current Physical Activity Guidelines for Adults:

Component	Minimum Recommendation	Details
Aerobic Activity	150–300 minutes/week	Moderate-intensity activity
	OR 75–150 minutes/week	Vigorous-intensity activity
Resistance Training	2 or more days/week	Moderate or greater intensity, involving all major muscle groups.

Higher volumes of aerobic activity increase the overall ‘flux’ (or rapid clearance) of lipoprotein particles from the blood. Interestingly, while high-volume activity has been shown to increase Coronary Artery Calcium (CAC) levels on scans, this is not a negative finding. Instead, it’s associated with lower overall risk, suggesting that intense exercise has a plaque-stabilizing effect—it’s converting soft, vulnerable plaque into safer, hard plaque. Some studies have even shown evidence of plaque regression (shrinkage) from high-volume aerobic exercise.  In this context, a higher CAC score in a high-performing athlete does not carry the same risk as the same score in a sedentary individual.

Ultimately, exercise is an essential part of long-term risk reduction, working synergistically with diet and medication, when needed.

Action: Aim for at least 150 minutes of “Zone 2” aerobic activity per week to compliment your strength training. This intensity – where you can still carry on a strained conversation – is the sweet spot for moderate intensity conditioning, which improves cardiorespiratory fitness without causing a bunch of fatigue that can interfere with strength gains.

Step 5: Supplements & Medications for Lowering Blood Cholesterol

Supplements

Many people look to over-the-Counter supplements to help manage their cholesterol. However, this entire category requires caution because it operates under looser regulatory oversight than prescription medications. Supplements are poorly regulated for purity, potency, or content, leading to large variations in active ingredients and a risk of contamination.

Red Yeast Rice (RYR)

Red Yeast Rice Extract lowers cholesterol primarily because it contains Monacolin K, a compound chemically identical to the active ingredient in the prescription statin lovastatin.  Since it offers no advantage over a proven prescription drug and carries the added downsides of unreliable dosing and contamination risk common to supplements, we do not recommend its use.

Citrus Bergamot

Citrus bergamot has shown modest effectiveness in lowering blood cholesterol levels. However, like many other supplements, it faces issues with unreliable dose concentration and purity.

More importantly, while it may lower lab numbers, it has never been proven to actually lower the risk of cardiovascular events like heart attacks. Therefore, it does not offer a clear advantage over more established options to strongly recommend its use.

Omega-3 Fatty Acids (Fish Oil)

General over-the-counter fish oil supplements lack strong evidence to support their use for high cholesterol or preventing heart attacks in the general population. In supplemental forms, these often contain unreliable dose concentrations and carry risk of contamination. 

In contrast, prescription-grade formulations used at high doses are purified and have robust clinical evidence showing a benefit for heart health in specific high-risk patients. These prescription therapies are discussed further below.

Plant Sterols & Stanols (Phytosterols)

Plant sterols and stanols (known together as phytosterols) are plant-derived compounds that are structurally similar to animal-derived cholesterol. They are available in supplement form or incorporated into fortified foods, like some margarines.

• How they work: When consumed, plant sterols “compete” with cholesterol for absorption in the intestine and can lower intestinal cholesterol absorption by 30-45%. 
• Effective dose: Phytosterol intakes of 2 to 3 grams per day lower blood LDL-C levels by 9-12% as long as intake is sustained.
• Safety note: There has been some controversy regarding high blood levels of phytosterols and cardiovascular risk. This is mainly a concern for patients with a very rare genetic condition called sitosterolemia (which affects about 0.05% of the population). For the vast majority of people, consuming plant sterols as part of a risk management strategy is considered safe and beneficial. If there is a clinical suspicion of sitosterolemia, a simple blood measure of phytosterols can be performed.

Prescription Drugs

For many patients, particularly those in high- and very high-risk categories, diet and exercise alone simply aren’t enough to reach aggressive LDL-C targets. In these cases, medication is necessary to lower long-term risk. Here is an overview of the main pharmacological options and treatment strategies

Statins

Statins are the most prescribed and most well-studied class of cholesterol drugs. They work by blocking HMG-CoA reductase, an enzyme the liver uses to produce cholesterol. When the liver’s internal cholesterol supply drops, it responds by upregulating (increasing) the number of LDL receptors on its surface. These receptors act like “magnets” that pull LDL and ApoB particles out of the blood and into the liver for disposal. The increase in receptor density is the primary reason statins are so effective at lowering your cholesterol numbers and reducing the risk of heart attacks, strokes, and cardiovascular death.

Statins are highly effective: for every 38 mg/dL (1 mmol/L) lowering of LDL-C, they reduce major cardiovascular events by 25-30%. This relationship has been definitively established by the Cholesterol Treatment Trialists’ (CTT) Collaboration meta-analyses, which synthesized data from over 170,000 participants and showed that the benefit is directly proportional to the absolute reduction in LDL-C. All common statins are now generic. We categorize them by potency.

High-Potency Options (Rosuvastatin & Atorvastatin): These are best used in high-risk situations where maximum cholesterol lowering is needed. Maximum doses can achieve upwards of 65% LDL-C lowering. However, even very low doses (such as 2.5-5 mg rosuvastatin) can achieve significant results with minimal side effects.

Moderate-Potency Options (Pitavastatin & Pravastatin): These are useful when absolute maximal lowering isn’t required, or when patients experience side effects from the higher-potency options.

Pitavastatin in particular appears to have several unique benefits:

• Lower risk of drug-drug interactions, useful for those on multiple medications
• Neutral or beneficial effect on blood sugar (vs. other statins that can modestly increase blood sugar levels)
• Neutral or less impact on Lipoprotein(a) (vs. other statins that can increase Lp(a) levels by 10-20% on average)
• Lowest risk of statin-associated muscle symptoms
• For an excellent comparative review of pitavastatin vs. other statin options, see here.

Note that Simvastatin or Lovastatin are generally not used today, as they offer no advantages over newer options, and carry more significant downsides.

Dosing depends on your individual risk. While the highest-risk patients benefit most from aggressive lowering (and thus often require higher doses), there is a diminishing return on increasing the dose: each doubling of the statin dose only achieves an additional 6% LDL-C lowering.

Because of this, the most effective strategy often involves using low- or moderate-doses of a statin combined with a non-statin medicine (like ezetimibe, discussed next). This combination achieves similar (or greater) LDL-C and ApoB lowering, with a much lower risk of side effects than high-dose of one drug alone.
[Source]

A common concern with statin therapy is a modest increase in the risk of new-onset diabetes. However, the clinical picture is nuanced: this risk is almost exclusively seen in individuals who already have “pre-diabetes” or significant metabolic risk factors (like obesity or high blood sugar). For these patients, the cardiovascular protection provided by the statin tends to outweigh the risk of a slight increase in blood sugar. Furthermore, increasing levels of cardiorespiratory fitness have been shown to largely mitigate this effect, emphasizing the synergy between medication and lifestyle.

While statins are generally well-tolerated, some people experience side effects. The American College of Cardiology offers a tool to assess statin intolerance symptoms. Strategies for managing statin intolerance include:

• Switching to a different statin (such as pitavastatin) or non-statin agent
• Using lower statin doses, often combined with a non-statin drug like ezetimibe
• Less-frequent dosing, such as every other day or once-twice weekly. These dosing regimens can still lower LDL-C significantly
• Higher levels of cardiorespiratory fitness minimize the impact of statins on increasing blood sugar levels.
• There is inconclusive evidence on the use of supplements like CoQ10 or Vitamin D on treating statin-associated muscle symptoms or other intolerance symptoms.

While statins are the preferred first-line therapy, two niche situations may justify switching to non-statin agents earlier:

1. Extreme Lp(a) increase: Although a 10-20% increase in Lp(a) is common, the overall statin benefit still outweighs it. However, some patients experience much more dramatic increases. If Lp(a) rises more substantially, a switch to alternatives like PCSK9 inhibitors or ezetimibe may be considered.
2. Cognitive Concerns (Experimental): For patients with a strong family history of dementia, some experts monitor blood markers of cholesterol production, such as desmosterol and lathosterol. If these markers are extremely low (below the 20th percentile), a switch to non-statin options may be a reasonable strategy to address specific patient concerns, although this is not a standard, guideline-directed practice.”

Ezetimibe

Ezetimibe​​ is often the first non-statin medicine added to a treatment plan. It works by blocking the absorption of cholesterol in the small intestine, specifically targeting cholesterol from both bile and food.

• Dosing and Efficacy: It is dosed simply as 10 mg daily, is extremely well-tolerated, and reliably provides an additional 20% LDL-C reduction.
• Synergy with Statins: Statins, while lowering production, can cause the body to increase cholesterol absorption in the gut. Ezetimibe is an excellent partner to a statin because it prevents this counterproductive effect.

Statins and Ezetimibe are the “perfect pair” because they target the two ways your body maintains cholesterol levels. When a statin lowers the liver’s production, the body often attempts to compensate by increasing cholesterol absorption in the small intestine. Ezetimibe effectively closes this “back door” by blocking that intestinal absorption. This dual-pathway inhibition allows for significant LDL-C lowering even when using lower, better-tolerated doses of each medication.

Bempedoic Acid

Bempedoic acid (Nexletol)is an oral drug that inhibits cholesterol synthesis, similar to a statin, but only in the liver. Since it has no activity in muscle or other tissues, it lowers the risk of muscle aches.

• Efficacy: It reduces LDL-C by an average of 25% by itself, by an additional 18% when added to a statin, and by 40% when given in combination with ezetimibe.

PCSK9 Inhibitors (PCSK9i)

PCSK9 inhibitors are the most powerful class of non-statin drugs available, typically reserved for high-risk patients who need extreme cholesterol reduction or who cannot tolerate oral medications. These drugs prevent the body from breaking down LDL-receptors, leading to more rapid clearance of LDL-C from the bloodstream. 

PCSK9 inhibitors routinely lower LDL-C by 50%, with the added benefit of lowering Lipoprotein(a) by 18-36% (in contrast to statins’ Lp(a)-increasing effect). These medications have demonstrated significant reductions in heart attacks and strokes in landmark clinical trials, specifically the FOURIER trial (Evolocumab) and the ODYSSEY Outcomes trial (Alirocumab). These studies proved that even in patients already on high-potency statins, further lowering of ApoB-containing particles leads to additional cardiovascular protection

PCSK9 inhibitors also have evidence of inducing plaque regression (plaque shrinkage) in arteries. Current approved options include the injectable drugs Evolocumab, Alirocumab, and Inclisiran. Oral options are in late-stage clinical trials as of 2025.

Prescription Omega-3 Fish Oils

Omega-3 fatty acids include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which have impacts on inflammation, blood clotting, and triglyceride levels. The strongest evidence supports the use of high-dose EPA in ethyl ester form (known as icosapent ethyl) to reduce cardiovascular risk. Some additional evidence supports EPA/DHA combinations in ethyl ester form, whereas carboxylic acid forms do not show clear benefit.

Early Combination Therapy

A significant shift in modern lipid management is the move toward early combination therapy. Older methods relied on sequential escalation—gradually increasing the dosage of one drug and waiting months before adding a second agent—which exposed patients to unnecessary cumulative risk while they waited for goal levels.

Instead, simultaneous initiation of combination therapies (e.g., statin plus ezetimibe or a PCSK9i) are able to more potently and rapidly achieve blood lipid control, often using lower doses of each agent, with a lower risk of side effects. For example, combining a low dose of rosuvastatin (5-10 mg) with ezetimibe (10 mg) can achieve similar results with less side effects from a maximum dose of rosuvastatin alone.

Achieving very low blood cholesterol levels can actually reverse existing disease. Numerous studies have shown evidence of plaque regression (shrinkage) when very low levels of ApoB are achieved. A 1% reduction in plaque volume is associated with an 18% reduction in major cardiovascular events. This justifies aggressive combination treatment in higher-risk patients.

Older Therapies

Fibrates (Fenofibrate, Gemfibrozil) can be used in addition to statins therapy for severely elevated triglyceride levels (typically over 500 mg/dL), to lower the risk of pancreatitis. Fibrates have not shown compelling benefits for reducing cardiovascular risk on their own.

Niacin was historically used because it could raise HDL-C while lowering LDL-C. Incidentally, it does have some effect on lowering Lp(a) levels. However, it failed to show clear benefits on cardiovascular risk. High-dose, extended-release formulations also increase the risk of acute liver failure.

Cholestyramine is a bile-acid sequestrant that works by binding cholesterol from bile in the intestines, similar to Ezetimibe, reducing its reabsorption. However, its dosing is complex (it comes as a powder that must be mixed) and it can interfere with the absorption of other medications. It is still used to manage diarrhea after gallbladder removal, but rarely used for cardiovascular management.

Action: If you are prescribed a statin and are concerned about side effects, discuss combination therapy with your physician. Each doubling of a statin dose only yields about 6% more lowering but increases side-effect risk. Ask if a low-dose combination (e.g., 5mg Rosuvastatin + 10mg Ezetimibe) is appropriate for your risk profile to maximize results while minimizing “statin aches.”

Step 6: Monitoring Changes in Blood Cholesterol Levels After Treatment

After initiating medication therapy or adjusting doses, changes to your blood lipids become apparent relatively quickly, within days to weeks.

• Initial Follow-up: It’s reasonable to repeat a full lipid panel within 6-12 weeks to observe the full effect of the changes.
• Ongoing Monitoring: Once you’ve achieved a stable, goal-directed lipid profile, monitoring can be repeated at longer intervals, unless there are significant changes to your health or medications in the interim.

Remember that managing cholesterol is only one component of heart health. Other parameters should also be assessed, including resting blood pressure, blood glucose, and markers of insulin resistance. Consulting with an experienced physician can guide this assessment and risk management plan over time.

Conclusion

Managing your heart health is a lifelong process. To help you stay on track, we have condensed this guide into a simplified, one-page Cholesterol Action Plan that you can download for FREE.

Key Principles

1. Personalized Targets: Management is not defined by achieving a single, generic number, but by aggressively reducing LDL-C and ApoB to a personalized target based on your risk estimates, personal goals, and preferences.
2. Laying the Foundation: The approach involves optimizing the metabolic environment through high-fiber, low-saturated fat nutrition and sufficient physical activity.
3. Leveraging Medication: Second, it involves using medicines, often through early use of drug combinations, to quickly meet blood lipid targets, particularly for high-risk patients.
4. Precision Risk Assessment: Utilizing advanced biomarkers and imaging tools allows for precise stratification of risk, facilitating a shared decision-making process regarding lifelong therapy.

By managing lipids within the context of overall metabolic and cardiovascular health, you can proactively and aggressively reduce your lifetime risk of atherosclerotic cardiovascular disease.